New combo therapy targets advanced lung cancer after relapse
NCT ID NCT03003468
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of two drugs—pembrolizumab (Keytruda) and Imprime PGG—in 35 people with advanced non-small cell lung cancer whose disease had worsened after initial treatment. The goal was to find a safe dose and see if the combination could slow cancer growth. The trial was completed and looked at side effects and how long patients lived without their cancer getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda) and Imprime PGG
What this could lead to
If successful, this combination could offer a new treatment option for advanced lung cancer patients whose disease has worsened after initial therapy.
What could go wrong
This is an early-phase trial with only 35 participants, so results may not apply broadly. The combination may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Indiana Univeristy Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Penn State Cancer Institute
Hershey, Pennsylvania, 17033, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University of Illinois at Chicago
Chicago, Illinois, 60612, United States
-
University of Iowa Hospital and Clinics
Iowa City, Iowa, 52242, United States